References to Primarv Literaturess
- BURTON SW: Int. Clin. Psycbopharmacol. (1991) 6 (Suppl3): 1–17.
- STOKES PE: Clin. Ther. (1993) 15: 216–43.
- MILNE RJ, GOA ICI: Drugs (1991) 41: 450–477.A good review of preclinical pharmacology and clinical effects of citalopram as well as SSRIs as a class.
- MURDOCH D, MCTAVISH D: Drugs (1992) 44: 604–624.
- DECHANT KL, CLISSOLD SP: Drugs (1991) 41: 225–253.
- •Good review of paroxetine; good discussion of adaptive changes in serotonin receptors following long-term SSRI administration.
- FULLER RW, WONG DT, ROBERTSON DW: Med. Res. Rev.(1991) 11: 17–34. Reviews structure-activity relationships for fluoxetine and summa-rizes therapeutic indications other than depression.
- RUDORFER MV, POTTER WZ: Drugs (1989) 37: 713–738.
- CHUMPRADIT S, KUNG MP, PANYACHOTIPUN C, PRAPAN-SIRI V, FOULON C, BROOKS BP, SZABO SA, TEJANI-BUIT S, FRAZER A, KUNG HF: J. Med. Chem. (1992) 35: 4492–4497.
- KUNG MP, CHUMPRADIT S, BILLINGS J, KUNG H: Life Sci. (1992) 51: 95–106.
- WONG DT, BYMASTER FP, MAYLE DA, REID LR, ICRUSHIN-SKI JH, ROBERTSON DW: Neuropsychopharmacol. (1993) 8: 23–33.
- VALENTA V, VLKOVA M, VALCHAR M, DOBROVSKY K, POLIVKA Z: Collect. Czech. Chem. Commun. (1991) 56: 1525–1533.
- MICHALS DR, SMITH HE: Chirality (1993) 5: 20–23.
- JILEK J, SINDELAR K, POMYKACEK J, ICMONICEK V, SEDIVY Z, Hrubantova M, HOLUBEK J, SVATEK E, RYSKA M, KORUNA I, VALCHAR M, DLABAC A, METYSOVA J, DLOHOZKOVA N, PROTIVA M: Collect. Czech. Cbem. Com-mun. (1989) 54: 3294–3338.
- SINDELAR K, KMONICEK V, TIRUBANTOVA M, POLIVKA Z:Collect. Czech. Chem. Commun. (1992) 57: 194–203.
- SINDELAR K, POMYKACEK J, HOLUBEK J, SVATEK E, VALCHAR M, DOBROVSKY K, METYSOVA J, POLIVKA Z: Collect. Czech .Chem. Commun. (1991) 56: 459–477.
- LEMBERGER L, FULLER RW, ZERBE RE: Clin. Pharmacol.(1985) 8: 299–317.
- HOGBERG T, ROSS SB, STROM P, BRUNEWALD GL, CREESE MW, BUNCE JD: J. Med. Chem. (1988) 31: 913–919.
- HANSCH C, CALDWELL J: J. Comput. Aided Mol. Des. (1991) 5: 441–453.
- MARCUSSON JO, NORINDER U, HOGBERG T, ROSS SB: Eur.J. Pharmacol. (1992) 215: 191–198. QSAR analysis of zimeldine analogues.
- KAISER C, SETLER PE: Antidepressant Agents In: Burger's Medicinal Chemistry, 4th Ed. (1981). WOLFF ME, (Ed.), Wiley & Sons, New York: 1044–1045.
- JOHNSON MP, FRESCAS SP, OBERLENDER R, NICHOLS DE:J. Med. Chem. (1991) 34: 1662–1668.
- FULLER RW, SNODDY HD, ICRUSHINSKI JH, ROBERTSON DW: Neuropharmacol. (1992) 31: 997–1000.
- WONG DT, BYMASTER FP, REID LR, MAYLE DA, KRUSHIN-SKI JH, ROBERTSON DW: Neuropsychopharmaca (1993) 8: 337–344.
- WELCH WM, KRASKA AR, SARGES R, KOE BK: J. Med. Chem.(1984) 27: 1508–1515.
- HYTTEL J, BOGESO KP, PERREGAARD J, SANCHEZ C: J.Neural. Transm. Gen. Sect. (1992) 88: 157–160.
- SHANK RP, VAUGHT JL, PELLEY KA, SETLER PE, MCCOM-SEY DF, MARYANOFF BE: J. Pharmacol. Exp. Therap. (1988) 247: 1032–1038. Good comparative reuptake, receptor binding, and in vivo pharma-cology for a number of SSR1s.
- MARYANOFF BE, VAUGHT JL, SHANK RP, MCCOMSEY DF, COSTANZO MJ., NORTEY SO: pled.Chem. (1990) 33: 2793–2797.
- SMITH DF, JENSEN PN, POULSEN SH, MIKKELSEN EO,ELBAZ E, GLASER R: EurJ.Pharmacol. (1991) 196: 85–92.
- HABERT E, GRAHAM D, TAHRAHOUI L, CLAUSTRE Y,LANGER SZ: Eur. J. Pharmacol. (1985) 118: 107–114. Evidence that paroxetine labels the 5-HT reuptake transporter, ranks potency of several SSRls.
- BLEGON A, MATHIS C: Synapse (1993) 13: 1–9.
- GOBBI M, CERVO L, TADDEI C, MENNINI T: Neurocbem. Int. (1993) 23: 247–251.
- HRDINA PD, FOY B, HEPNER A, SUMMERS RJ:J. Pbarmacol, Exp. Ther. (1990) 252: 410–418.
- SUEHIRO M, WILSON AA, SCHEFFEL U, DANNALS RE, RAVERT HT, WAGNER HN, JR: Int.J. Rad. Appl. InstrumMl. (1991) 18: 791–796.
- MATHIS CA, GERDES JM, ENAS JD, WHITNEY JM, TAYLORSE, ZHANG Y, MCKENNA DJ, HAVLIK S, PEROUTKA SJ: Pharm. Pharmacol. (1992) 44: 801–805. Ranks methyl-substituted paroxetine derivatives for in vitro potency.
- D'AMATO RJ, LARGENT BL, SNOWMAN AM, SNYDER SH: J. Pharmacy!. Exp. Then (1987) 242: 364–371.
- KOE BK, LABEL LA, WELCH WM: Psychopbarmacol. (1990) 100: 470–476.
- HASHIMOTO K, GOROMARU T: J. Pharmacol. Exp. Ther. (1990) 255: 146–153.
- HASHIMOTO K, GOROMARU T: Eur. J. Pharmacy!. (1990) 180: 273–281.
- HASHIMOTO K, GOROMARU T Neuropharmacol. (1991) 30:113-117. Evidence that 6-nitroquipazine labels the 5-HT reuptake transporter; ranks potency of several SSRIs.
- HASHIMOTO K, GOROMARU T Neurophartnacol. (1992) 31: 869–874.
- MATHIS CA, TAYLOR SE, BIEGON A, ENAS JD: Brain Res.(1993) 619: 229–235.
- BLEGON A, MATHIS CA, HANRAHAN SM, JAGUST WJ: BrainRes. (1993) 619: 236–246.
- SUEHIRO M, SCHEFFEL U, DANNALS RF, RAVERT HT, RICAURTE GA, WAGNER HN, JR: J. Nucl. Med. (1993) 34: 120–127.
- WALDMETER PC, BAUMANN PA: Naunyn Schmiedeberg Arch. Pharmacol. (1983) 324: 20–26.
- WALDMEIER PC, STOCKLIN K: Eur. J. Pharmacol. (1989) 169: 197–204.
- WALDMEIER PC, GRAF T, GERMER M, FELDTRAUER JJ, HOWALD H: Biol. Psychiatry (1993) 33: 373–379.
- WALDMEIER PC: Prog. Neuropsychopharmacol. Biol. Psy-chiatry(1993) 17: 183–198.
- ANGEL I, SCHOEMAKER H, PROU'TEAU M, GARREAU M, LANGER SZ: Surf. Pharmacol. (1993) 232: 139–145.
- ANZINI M, CAPPELLI A, VOMERO S, CAMPIANI G., C.AG-NOTTO, A., SKORUPSKA MZ: Farmaco. (1991) 46: 1435–1447.
- MALLERON JL, GUEREMY C, MIGNANI S, PEYRONEL JF,TRUCHON A, BLANCHARD JC, DOBLE A, LADURON P, PIOT 0, ZUNDEL JL, BETSCHART J, CANARD H, CHAILLOU P, FERRIS 0, HUON C, JUST B, KERPHIRIQUE R, MARTIN B, MOUTON P, RENAUDON A: J. Med. Chem. (1993) 36: 1194–1202.
- EISON AS, EISON MS, TORRENTE JR, WRIGHT RN, YOCCA D: Psychopharmacol. Bull. (1990) 26: 311–315.
- DEFRANCE R, MAREY C, KAMOUN A: Clin. Neuropharma-col. (1988) 160 (suppl. 15): S74–S82.
- MENNINI T, MOCAER E, GARATTINI S: Naunyn Schmiede-berg Arch. Parmacol. (1987) 336: 478–482.
- PUIG S, RIVOT JP, BESSON JM: Brain Res, (1993) 600: 219–224.
- BROQUA P, BAUDRIE V, CHAOULOFF F: Eur. Neuropsycho-pharmacol. (1992) 2: 115–120.
- ZOHAR J, ZOHAR-KADOUCH RC, KINDLER S: Drugs (1992) 43: 210–218.
- SCHNEIER FR, LIEBOWITZ MR, DAVIES SO, FAIRBANKS J,HOLLANDER E, CAMPEAS R, KLEIN DF: J. Clin. Psychophar-macol. (1990) 10: 119–121.
- WESTENBERG HG, DEN BOER JA: Pharmacopsychiatry (1993) 26 (Suppl 1): 30–33.
- WISE SD: Am. J. Clin. Nutr. (1992) 55: 181S–184S.
- RAMIREZ LC, ROSENSTOCK J, STROWIG S, CERCONE S, RASIUN P: Am. J. Med. (1990) 88: 540–541.
- POTTER VAN LOON BJ, RADDER JK, FROLICH M, KRANS HM, ZWINDERMAN AU, MEINDERS AE: Int.J. Obes. (1992) 16: 79–85.
- MEINDERS AE, PIJL H: Mt, J. Obes. (1992) 16 (Suppl 4): S35–S39.
- BLAKELY RD, BERSON 11E, FREMEAU RT jR, CARON MG,PEEK MM, PRINCE HK, BRADLEY CC: Nature (1991) 354: 66–70. Cloning and expression of the rat 5-HT transporter in HeLa fi-broblasts and inhibition of 5-HT transport by SSRIs.
- HOFFMAN BJ, MEZEY E, BROWNSTEIN MJ: Science (1991)254: 579–580. Cloning and expression of the rat 5-HT transporter in CV-1 cells and inhibition of 5-HT transport by SSRls.
References to Patent Literature
- UNIVERSITY OF PENNSYLVANIA, W09219210 (1992).
- ELI LILLY & CO, EP-273658-A (1988); US5023269 (1991).
- ELI LILLY & CO, EP-318233-A (1989).
- ELI LILLY & CO, US4902710 (1990).
- ELI LILLY & CO, EP-336753-A (1990).
- HOECHST-ROUSSEL PHARMACEUTICALS INC, US5229417 (1993); EP-545425-A1 (1993).
- ELI LILLY & CO, U55135947 (1992).
- ELI LILLY & CO, EP-318234-A (1989).
- CIBA-GEIGY CORP, US4824868 (1989).
- MERRILL DOW PHARMACEUTICALS INC, US5149714 (1992); EP- 303961-A (1989).
- HOECHST-ROUSSEL PHARMACEUTICALS INC, US5202319 (1993); EP-534344-A1 (1993).
- SPOFA SPOJENE PODNI, AU8934706-A (1990).
- AKZO NV, EP-516234-Al.
- WELLCOME FOUNDATION LTD, W09312080 (1993); EP-402097-A (1990).
- ELI LILLY & CO, EP-343830-A (1989).
- BRISTOL-MYERS SQUIBB, EP-464604-A (1992).
- HOECHST-ROUSSEL PHARMACEUTICALS INC, EP-498331-Al (1992).
- ALBERT ROLAND SA, FR2665700–A
- HOECHST-ROUSSEL PHARMACEUTICALS, INC, U55264576
- SEPRACOR INC, US5104899 (1992); W09309769 (1993).
- ELI LILLY & CO, EP-369685-A (1990); EP-444855-A (1991).
- FERROSAN, US4007196 (1977).
- LUNDBECK, EP-347066-A (1989).
- ABBOTT, W09312754 (1993); US5140040 (1992).